Online inquiry

IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5143MR)

This product GTTS-WQ5143MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL1RAP gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001167928.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3556
UniProt ID Q9NPH3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5143MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10730MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ7595MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ9148MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ13354MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ15843MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ3300MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ4799MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BT 5/9
GTTS-WQ5859MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW